NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 421
(Total Views: 210)
Posted On: 04/19/2022 3:37:21 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences Its Most Comprehensive Study to Date
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has begun its multi-week human clinical hypertension study. The randomized, double blinded, placebo-controlled, cross-over study in 60 people, HYPER-H21-4, is the most comprehensive study ever undertaken by Lexaria. HYPER-H21-4 is designed to enhance Lexaria’s probability of success with its expected subsequent Investigational New Drug (“IND”) application filing to seek U.S. Food and Drug Administration (“FDA”) approval to commence registered clinical testing at phase I level or higher, to be determined in consultation with the FDA. The human study is also expected to enhance Lexaria’s understanding of DehydraTECH-CBD for the treatment of cardiovascular and other disease states beyond hypertension. Dosing has commenced in more than half of the HYPER-H21-4 volunteers, ahead of schedule, with all treatment visits expected to conclude in early July 2022. In addition, baseline brain magnetic resonance imaging (“MRI”) scanning has already begun. Of significant note, no serious adverse events have been reported by study volunteers, demonstrating that DehydraTECH-CBD has been well tolerated in those who have received it thus far.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has begun its multi-week human clinical hypertension study. The randomized, double blinded, placebo-controlled, cross-over study in 60 people, HYPER-H21-4, is the most comprehensive study ever undertaken by Lexaria. HYPER-H21-4 is designed to enhance Lexaria’s probability of success with its expected subsequent Investigational New Drug (“IND”) application filing to seek U.S. Food and Drug Administration (“FDA”) approval to commence registered clinical testing at phase I level or higher, to be determined in consultation with the FDA. The human study is also expected to enhance Lexaria’s understanding of DehydraTECH-CBD for the treatment of cardiovascular and other disease states beyond hypertension. Dosing has commenced in more than half of the HYPER-H21-4 volunteers, ahead of schedule, with all treatment visits expected to conclude in early July 2022. In addition, baseline brain magnetic resonance imaging (“MRI”) scanning has already begun. Of significant note, no serious adverse events have been reported by study volunteers, demonstrating that DehydraTECH-CBD has been well tolerated in those who have received it thus far.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)